• Telix changes reporting currency to USD to align with predominant revenue and cost base
• Recast historical financial information for FY2023 and FY2024 provided
• H1 2025 OPEX (excluding R&D) expected to be ~36% of revenue

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) provides an unaudited recast of its historical financial information in United States (U.S.) dollars (USD), following a change in reporting currency from Australian dollars, effective 1 January 2025. Telix elected to change its reporting currency to USD to align to the predominant currency used for reporting its revenue, costs and corresponding cash flows, which are primarily generated in the U.S. and denominated in USD. Telix is providing recast full-year and half-year information for financial years 2023 and 2024 on a voluntary, unaudited basis to assist investors with the transition. The recast historical financial information has been prepared using accounting policies consistent with those applied in the preparation of Telix's audited or reviewed consolidated financial statements for these periods. Telix's U.S. operations have expanded significantly following a number of acquisitions, including RLS Radiopharmacies, which completed on 27 January 2025. Telix advises that OPEX, excluding investment in research and development, is expected to be approximately 36% of revenue in H1 2025 (unaudited). This reflects the expanded business activities and the Company's ongoing strategy to reinvest earnings in commercial growth and pipeline development opportunities.